Your browser doesn't support javascript.
loading
Subacute oral toxicity and bacterial mutagenicity of a mixture of Puerariae radix and Hizikia fusiforme extracts.
Youn, Soo Hyun; Han, Chang-Kyun; Suh, Jae Hyun; Hyun, Sun Hee; Kyung, Jong-Soo; So, Seung-Ho; Kim, Jong-Han; Seo, Hwi Won.
Affiliation
  • Youn SH; Laboratory of Efficacy Research, Korea Ginseng Corporation, Daejeon, Republic of Korea.
  • Han CK; Laboratory of Efficacy Research, Korea Ginseng Corporation, Daejeon, Republic of Korea.
  • Suh JH; Laboratory of Efficacy Research, Korea Ginseng Corporation, Daejeon, Republic of Korea.
  • Hyun SH; Laboratory of Efficacy Research, Korea Ginseng Corporation, Daejeon, Republic of Korea.
  • Kyung JS; Laboratory of Efficacy Research, Korea Ginseng Corporation, Daejeon, Republic of Korea.
  • So SH; Laboratory of Efficacy Research, Korea Ginseng Corporation, Daejeon, Republic of Korea.
  • Kim JH; Laboratory of Efficacy Research, Korea Ginseng Corporation, Daejeon, Republic of Korea.
  • Seo HW; Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
Drug Chem Toxicol ; 45(5): 2193-2201, 2022 Sep.
Article in En | MEDLINE | ID: mdl-34219570
ABSTRACT
The study aims to identify the safety profile of a mixed extract (KGC-02-PS) from two traditional medicinal herbs, Puerariae radix and Hizikia fusiforme. In a subacute oral toxicity study, KGC-02-PS was administered orally for 28 days by gavage to Sprague Dawley rats (both sexes) at a daily dose of 0, 500, 1000, and 2000 mg/kg body weight. Bodyweight, food consumption, and clinical signs were monitored during the experimental period. After administering the final dose, this study conducted hematology, serum biochemistry, and pathological evaluations. In addition, the study performed a bacterial reverse mutation test with varying concentrations of KGC-02-PS (312.5 µg - 5,000 µg/plate) following OECD guideline No. 471, before testing five bacterial strains (Salmonella typhimurium TA98, TA100, TA1535, TA1537, and Escherichia coli WP2) in the presence or absence of metabolic activation. The preclinical evaluation of KGC-02-PS's subacute oral toxicity yielded no associated toxicological effects or any changes in clinical signs, body weight, and food consumption. Moreover, examining KGC-02-PS's hematological and serum biochemical characteristics and pathology yielded no toxicological changes in terms of organ weight measurements and gross or histopathological findings. KGC-02-PS neither increased the number of revertant colonies in all bacterial strains used in the bacterial reverse mutation test, nor did it induce genotoxicity related to bacterial reverse mutations under the study's conditions. Also, KGC-02-PS's no-observed-adverse-effect level was greater than 2000 mg/kg.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pueraria / Mutagens Type of study: Guideline / Prognostic_studies Limits: Animals Language: En Journal: Drug Chem Toxicol Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pueraria / Mutagens Type of study: Guideline / Prognostic_studies Limits: Animals Language: En Journal: Drug Chem Toxicol Year: 2022 Document type: Article